fda ind, page-54

"TT-034 has the ability, with a Global initiative, to eradicate HCV from existance within a generation. Something the competition simply cannot achieve."

Max, Mark Kay has is different view. According to his research shrna does not act on the neg strand of HCV RNA (I think DS has a different view). Additional research shows that the neg strand exists in blood cells ie, outside of the liver.

If this research is correct, it means that even if TT-034 works, it will need several more refinements before this laudable goal can be achieved. It may be TT-040 by that stage. But, as you say, other drugs probably don't have to same growth pathway that TT-034 does and this could be the point of distinction and a reason for big pharma to be interested.